Is Corcept Therapeutics, Inc. CORT stock halal to invest in?

Yes, as of August 2026, Corcept Therapeutics, Inc. stock (CORT) is classified as a Shariah compliant stock. This verdict follows the screening methodology of AAOIFI (the Accounting and Auditing Organization for Islamic Financial Institutions), whose Shariah Standard No. 21 is the leading global benchmark for screening halal stocks. Corcept Therapeutics, Inc. currently passes all four AAOIFI financial screens: non-permissible income remains below 5% of total revenue, interest-bearing investments and interest-bearing debt each remain below 30% of market capitalisation, and the company has no impermissible preference share structure. The stock's current purification factor is 100%. Compliance is reassessed every month as updated screening data arrives, and a stock's status can change when new financial reports are released. You can always check the current status of Corcept Therapeutics, Inc. and explore other Shariah compliant stocks in the Tabadulat app.

How often is Corcept Therapeutics, Inc. CORT reviewed for Shariah compliance?

Tabadulat reviews Corcept Therapeutics, Inc. CORT for Shariah compliance every month. Each review applies the AAOIFI Shariah Standard No. 21 methodology, screening the company's business activities, non-permissible income, interest-bearing investments, interest-bearing debt, and preference shares, against the company's latest available financial data. The process operates under the direct supervision of Tabadulat's dedicated Shariah Supervisory Board of Islamic finance scholars. Because compliance depends on financial ratios that move with market capitalisation and reported results, a stock's status can change from one review to the next. Monthly screening ensures the status shown for Corcept Therapeutics, Inc. reflects current financial data rather than an outdated assessment, and Tabadulat app users are notified if a holding in their portfolio becomes non-compliant.

Does Corcept Therapeutics, Inc. CORT pass the AAOIFI Non Permissible Income criteria?

Yes, as of August 2026, Corcept Therapeutics, Inc. stock (CORT) passes the AAOIFI non-permissible income screen. Under AAOIFI Shariah Standard No. 21, income from impermissible sources (such as interest or riba, conventional financial services, alcohol, gambling, or tobacco) must remain below 5% of a company's total revenue. Corcept Therapeutics, Inc.'s income from non-permissible sources is currently within this 5% threshold. Even permissible levels of incidental impure income should still be purified: investors donate the corresponding share of dividends to charity, as reflected in the stock's purification factor. This screen is reassessed monthly using the company's latest financial disclosures.

Does Corcept Therapeutics, Inc. CORT pass the AAOIFI Interest Bearing Investments criteria?

Yes, as of August 2026, Corcept Therapeutics, Inc. stock (CORT) passes the AAOIFI interest-bearing investments screen. Under AAOIFI Shariah Standard No. 21, the cash a company places in interest-earning instruments (such as conventional deposits, bonds, treasury bills and money-market funds) must remain below 30% of its market capitalisation. This limit ensures shareholders are not materially profiting from riba (interest). Corcept Therapeutics, Inc.'s interest-bearing investments are currently within the 30% threshold. Because the ratio is measured against market capitalisation, it can move with the share price as well as the balance sheet, which is why Tabadulat rescreens the stock every month.

Does Corcept Therapeutics, Inc. CORT pass the AAOIFI Interest Bearing Debt criteria?

Yes, as of August 2026, Corcept Therapeutics, Inc. stock (CORT) passes the AAOIFI interest-bearing debt screen. Under AAOIFI Shariah Standard No. 21, a company's borrowings that accrue interest (conventional bank loans, bonds and similar riba-based financing) must remain below 30% of its market capitalisation. This cap limits shareholders' exposure to interest-based leverage. Corcept Therapeutics, Inc.'s interest-bearing debt is currently within the 30% threshold. Because market capitalisation changes daily, a company's debt ratio can drift toward or away from the limit even without new borrowing, which is why this screen is reassessed every month.

What is the dividend purification factor for Corcept Therapeutics, Inc. CORT stock?

As of August 2026, the dividend purification factor for Corcept Therapeutics, Inc. (CORT) is 100%. Purification (tazkiyah) is the practice of donating to charity the portion of dividend income attributable to incidental non-permissible sources, typically interest earned on a company's cash, and AAOIFI methodology requires it even for fully compliant stocks. The purification factor is the figure halal investors use to work out that donation on Corcept Therapeutics, Inc. dividends. It is recalculated with each monthly screening as new financial data arrives, and the Tabadulat app can help you calculate and track purification across your whole portfolio.

Does Corcept Therapeutics, Inc. CORT pass the AAOIFI Preference Share screen?

Yes, as of August 2026, Corcept Therapeutics, Inc. stock (CORT) passes the AAOIFI preference share screen. AAOIFI Shariah Standard No. 21 prohibits investing in preference shares because they grant holders guaranteed or priority rights to dividends and capital ahead of ordinary shareholders, a structure that conflicts with the Shariah principle that investors should share profit and loss in proportion to their ownership. Corcept Therapeutics, Inc. has no impermissible preference share structure affecting its ordinary shares, so the stock is compliant on this criterion. Like all AAOIFI screens, this is verified in each monthly review.

Invest Halal, Anytime, Anywhere

Download the Tabadulat app and start building your Shariah-compliant portfolio in minutes.

English

العربية

Corcept Therapeutics, Inc.

NASDAQ

Shariah-Compliant

Not Shariah

CORT

About

Corcept Therapeutics, Inc.

CORT

Corcept Therapeutics Incorporated is a pharmaceutical company specializing in the research, development, and commercialization of innovative therapies that modulate cortisol activity. With over 25 years of experience and a portfolio that includes more than 1,000 proprietary molecules, the company focuses on unlocking the therapeutic potential of targeting the glucocorticoid receptor, which plays a central role in physiological and psychological processes regulated by cortisol, often referred to as the “stress hormone.” Corcept’s primary purpose is to address serious diseases that are impacted by abnormal cortisol function, spanning multiple sectors including endocrinology, oncology, metabolism, and neurology. Its marketed product, Korlym (mifepristone), is approved for controlling hyperglycemia in Cushing’s syndrome, and its pipeline features candidates for conditions such as nonalcoholic steatohepatitis, various cancers, and psychiatric disorders. Corcept Therapeutics is recognized for its scientific leadership in cortisol modulation and maintains a strong commitment to advancing novel solutions for unmet medical needs through extensive clinical research and collaboration within the global healthcare sector.

Sector:

Healthcare

Industry:

Biotechnology

Employees:

500

Website:

https://www.corcept.com

CORT

Frequently asked questions

Related stocks

Mobile login screen for Tabadulat with fields to enter email, a Continue button, an option to create an account, and a language selector showing EN.

Step 1

Open your account.

Create your Tabadulat account in minutes: enter your details, complete identity verification, and add funds by secure transfer in multiple currencies. You're ready to start investing in halal stocks the same day.

Mobile screen showing add money interface with 100 AED amount and Manual Bank Transfer payment method selected, noting 1-2 business days processing.

Step 2

Deposit.

Add funds to your account using a secure payment method. You can deposit in multiple currencies to get started.

Step 3

Screen.

Screen Stocks for Free and explore a wide range of stocks that are ethically screened for Shariah compliance. Use our Halal Stock Screener to find the best opportunities.

Corcept Therapeutics, Inc.

About

Corcept Therapeutics, Inc.

CORT

Frequently asked questions

Is Corcept Therapeutics, Inc. CORT stock halal to invest in?

How often is Corcept Therapeutics, Inc. CORT reviewed for Shariah compliance?

Does Corcept Therapeutics, Inc. CORT pass the AAOIFI Non Permissible Income criteria?

Does Corcept Therapeutics, Inc. CORT pass the AAOIFI Interest Bearing Investments criteria?

Does Corcept Therapeutics, Inc. CORT pass the AAOIFI Interest Bearing Debt criteria?

What is the dividend purification factor for Corcept Therapeutics, Inc. CORT stock?

Does Corcept Therapeutics, Inc. CORT pass the AAOIFI Preference Share screen?

How do I buy Corcept Therapeutics (CORT) stock?

Open your account.

Deposit.

Screen.